Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the ...

Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...

Novo Nordisk A/S is undercutting arch-rival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness ...

Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a ...

Novo Nordisk and Eli Lilly denied weight-loss drug partnership with Mangoceuticals on Thursday, hours after the telehealth ...

The Trump administration on Thursday rolled out a much-anticipated deal with drugmakers Eli Lilly and Novo Nordisk that aims ...

Eli Lilly (LLY) stock is trading at record highs after the pharmaceutical company reached a deal with the White House to ...

Novo Nordisk and Eli Lilly deny partnership with Mangoceuticals for weight-loss drugs, causing Mangoceuticals' shares to ...

Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...